Member Info for EmeraldCarrots

FDA application update will be key. Opening up the entire USA market is eveything.

To place an order with Angle Plc to carry out the dual analysis (that has now been independently corroborated by the National and Kapodistrian University of Athens) during their next cancer drug trial . Clearly Astra wanted independent corroboration of the RNS dated 4th January:-

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

Corroboration RNS:-

https://angleplc.com/wp-content/uploads/2024/11/2024-Ntzifa-LB-analysis-for-monitoring-NSCLC-patients-under-2nd-line-osimertinib-1.pdf

The facts are there for all to see. The markets eyes are clearly shut! It won't necessarily be Astrazeneca. Most likely, but it could be Eisai Inc. They have shown themselves to lead from the front already. But maybe another massive Pharma will want to further evaluate the dual analysis? Potentially massive savings evaluating cancer drug trial candidates to see if they are suitable. No point in accepting participants if after re-evaluation just before the trial they no longer meet the criteria. It's so obvious. Massive savings on doing the trial. Then invaluable feedback on the drugs performance during the trial and after.

The sp is beyond ridiculous.

All IMHO

Up 5.25%.

Woops. despair, not dispair.

Here. The next few RNS's I presume will make the penny drop. It really is totally and utterly ridiculous IMHO.

Mad.

Yes. We are on the otc as well.

https://www.otcmarkets.com/stock/ANPCY/overview

Several after quite a lull.

With Angle Plc to carry out the dual analysis (that has now been independently corroborated by the National and Kapodistrian University of Athens) during their next cancer drug trial . Clearly Astra wanted independent corroboration of the RNS dated 4th January:-

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

Corroboration RNS:-

https://angleplc.com/wp-content/uploads/2024/11/2024-Ntzifa-LB-analysis-for-monitoring-NSCLC-patients-under-2nd-line-osimertinib-1.pdf

That RNS will be rather good for the sp...... Plain sailing from there until I presume a takeover bid. And if that happens it will be multiples of the current sp (9.5p). We are looking at 50 to 80p a share, I think.

All IMHO.

With Angle Plc to carry out the dual analysis that has now been independently corroborated by the National and Kapodistrian University of Athens during their next cancer drug trial . Clearly Astra wanted independent corroboration of the RNS dated 4th January:-

https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html

That RNS will be rather good for the sp...... Plain sailing from there until I presume a takeover bid. And if that happens it will be multiples of the current sp (9.5p). We are looking at 50 to 80p a share, I think.

All IMHO.

Good morning!

Hello.

Even if there is nothing wrong with them. Write the post but before you actually post it copy it to your emil and send it to yourself. Then if it is removed you can easily post it up again.

- here we go again?

All IMHO.

At least anyone who got "spiked" knows the sp has nudged 3p on a number of occasions in the last SEVERAL weeks. All not lost.

All IMHO.

At least anyone who got "spiked" knows the sp has nudged 3p on a number of occasions in the last few weeks. All not lost.

All IMHO.

At least anyone who got "spiked" knows the sp has nuged 3p on a nomber of occasions in the lest few weeks. All not lost.

And dump? That one only took 3.5 Hrs! LOL!

Systemzero.

Be careful. You might get told off by Popeye62, and then get insulted by Guy_incognito who brings far less to this board than me. You have been warned... LOL!!

Up 9.18%.

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=GDR.L#google_vignette